Monday, December 5, 2016

Impel NeuroPharma Finds $36M

Seattle-based Impel Neuropharma, the biotechnology startup developing intranasal drug treatments for central nervous (CNS) disorders, said late last week that it has raised $36M in a Series C funding. The funding came from venBIO, 5AM Ventures, and Vivo Capital. Impel Neurpharma said the funding is broken into two tranches, one worth $21M and another $15M contingent on certain development and business milestones.